menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Renhui Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renhui Bio Announced that the Application for the Marketing of Benaglutide Injection for Weight Loss Indications has been Accepted in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Beinaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Shanghai Renhui Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Renhui Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Renhui Biopharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Renhui Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Clinical Application for the New Pump Administration Method of Benaglutide for Weight Loss Indications was Approved","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Beinaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Shanghai Renhui Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Renhui Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Renhui Biopharmaceutical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Shanghai Renhui Biopharmaceutical

    Menu

    Shanghai Renhui Biopharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shanghai Renhui Biopharmaceutical

                            China arrow
                            Discovery on Target
                            Not Confirmed

                            Shanghai Renhui Biopharmaceutical

                            China arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beinaglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renhui Bio Announced that the Application for the Marketing of Benaglutide Injection for Weight Loss Indicatio...

                            Details : Yishengtai (benaglutide) is a fully human GLP-1 drug, which mainly used for weight loss effect in the clinical use of type 2 diabetes and comprehensive benefits for overweight and mechanisms such as enhancing satiety, delaying gastric emptying.

                            Brand Name : Yishengtai

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 15, 2022

                            Lead Product(s) : Beinaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shanghai Renhui Biopharmaceutical

                            China arrow
                            Discovery on Target
                            Not Confirmed

                            Shanghai Renhui Biopharmaceutical

                            China arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beinaglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            The Clinical Application for the New Pump Administration Method of Benaglutide for Weight Loss Indications was...

                            Details : Yishengtai (benaglutide) is a fully human GLP-1 drug, which mainly used for weight loss effect in the clinical use of type 2 diabetes and comprehensive benefits for overweight and mechanisms such as enhancing satiety, delaying gastric emptying.

                            Brand Name : Yishengtai

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 08, 2021

                            Lead Product(s) : Beinaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth